Edumed s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Edumed s.r.o. in Nachod, clinical research in cardiovascular diseases focuses on major conditions such as atherosclerotic cardiovascular disease, heart failure, and related risk factors. These studies are designed to test new therapies that may lower the chance of serious heart events and improve long-term outcomes for people at elevated cardiovascular risk.
- Preventing major adverse cardiovascular events in high-risk patients
- Improving care for heart failure with preserved or mildly reduced ejection fraction
- Reducing risk linked to elevated lipoprotein(a) and systemic inflammation
Research here also includes studies aimed at better managing obesity-related cardiovascular complications and assessing whether emerging treatments can support standard care more effectively.
Nutritional and Metabolic Diseases
The site has a strong focus on nutritional and metabolic diseases, especially obesity, overweight, type 2 diabetes, and hypertriglyceridemia. Trials in this area are testing new options to improve weight management, lipid control, and blood sugar outcomes in everyday clinical practice.
- Evaluating treatments for severe and persistent high triglycerides
- Studying weight-loss approaches for people with obesity or overweight
- Assessing diabetes care strategies that may improve glucose control and treatment balance
Several studies also explore how metabolic therapies may reduce future cardiovascular and kidney complications, reflecting the close connection between these conditions.
Immune System Diseases
Clinical trials in immune system diseases at this hospital/clinic include research on Graves’ disease, a thyroid disorder driven by immune activity. These studies are intended to evaluate new ways to restore and maintain normal thyroid function while reducing the need for ongoing treatment.
- Testing therapies for better control of Graves’ disease
- Exploring options to maintain euthyroidism over time
- Assessing safety and tolerability of immune-focused treatments
This area of research supports more precise management of autoimmune thyroid disease and may help improve quality of life for affected patients.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Research in congenital, hereditary, and neonatal diseases and abnormalities is represented through studies of inherited or biologically driven conditions that affect metabolism, cardiovascular risk, and endocrine health. At Edumed s.r.o., these trials aim to deepen understanding of disease-related pathways and support more targeted treatment approaches.
- Investigating inherited risk factors linked to cardiovascular and metabolic disease
- Supporting earlier recognition of conditions with a hereditary component
- Evaluating therapies that may address underlying biological drivers of disease
Although less prominent than the cardiometabolic portfolio, this field adds important breadth to the site’s clinical research program.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1AstraZeneca AB6active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB12trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Edumed s.r.o.
lock Showing 1 of 47 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized Study of IMVT-1402 Versus Placebo in Adult Patients with Graves' Disease | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 6 | Unknown | 2023-08-02 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.